Trial intelligence / Profile preview

Intrapleural fibrinolysis and DNase versus VATS for pleural empyema

2024-513596-40-00Phase 4Authorised

Sponsor: University Hospital Odense
Start: Jun 2024
Modality: Recombinant Proteins and Enzymes
Countries: 1

Overview

Phase 4, randomised, open-label trial of dornase alfa and tissue-plasminogen activator in Empyema Thoracis (2 arms), sponsored by University Hospital Odense. Planned start Jun 2024; status: authorised.

Drugs

dornase alfatissue-plasminogen activator

Conditions

Empyema Thoracis

Beyond the preview

Go deeper on 2024-513596-40-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-513596-40-00.